Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
The table below compares immune-modulating peptides by pathway, target tissue, and documented research outcomes. Thymalin Upregulates thymulin production in thymic epithelial cells Thymus gland, T-cell maturation Restored CD4/CD8…
Before selecting a secretagogue, understand the trade-offs between receptor specificity, half-life, and secondary hormonal effects. CJC-1295 (no DAC) GHRH analog. Direct pituitary stimulation 30 minutes 100–200mcg 2–3×/day Minima…
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist Hypothalamus (dopamine pathways) 45–60 minutes subcutaneous FDA-approved; Phase 3 RCTs in 1,267 women Strongest evidence for generalized low libido in premenopausal women; wo…
Thymalin Thymulin receptor agonist. Promotes T-cell maturation in thymic tissue Thymic epithelial cells, T-lymphocyte progenitors 5–10mg per injection 2–3 times weekly Phase 2 trials showing 34% naive T-cell increase over 8 weeks…
GHK-Cu (Copper Peptide) DHT receptor blockade + TGF-β upregulation Androgenetic alopecia (pattern baldness) Topical post-microneedling 2–3× weekly, 1% concentration Gold standard for miniaturised follicle reversal. Best evidence …
Pinealon Upregulates AANAT enzyme in pineal cells → increases endogenous melatonin synthesis Moderate (acts within 2–3 weeks) High (sustained endogenous production) Low (no receptor saturation) Best for long-term circadian restor…
| Peptide | Mechanism | Half-Life | Typical Dosing Protocol | Secondary Hormonal Effects | Desensitization Risk | Research Application ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog | 6–8 days | 1–2 mg once weekly | Minimal—GH…
Cerebrolysin BDNF/NGF mimetic. Neurotrophic receptor activation Human RCTs in TBI populations Intravenous infusion 12% improvement in favorable outcomes (GOS 4–5) at 6 months in pooled analysis of 2,117 patients Approved for TBI …
Thymalin Thymic restoration, T-cell maturation Immune senescence, SASP reduction Phase II: 34% increase CD4+ T-cells, 22% reduction SASP markers (12 weeks, Immunity & Ageing 2021) 10mg subcutaneous, twice weekly Most overlooked d…
Before selecting peptides for detoxification research, compare their mechanisms, bioavailability, and documented outcomes. Not all peptides target the same detox pathways—some enhance antioxidant enzyme transcription, others supp…
This table compares peptide candidates under investigation for anxiolytic effects based on mechanism, bioavailability, administration route, and current evidence quality. Selank Opioid receptor modulation (mu/delta), HPA axis dow…
The table below compares the most clinically validated peptides for appetite and craving suppression based on mechanism, dosing, half-life, and documented efficacy. Semaglutide GLP-1 receptor agonist. Delays gastric emptying, sup…
Timing determines which peptides matter. Acute-phase interventions (0–14 days post-injury) target excitotoxicity and blood-brain barrier stabilisation. Chronic-phase protocols (2+ months post-injury) focus on neuroplasticity, den…
Before selecting a peptide for ulcer healing, compare the mechanisms, dosing standards, and evidence base for the most-researched compounds. BPC-157 Stimulates VEGF and fibroblast growth factor; promotes angiogenesis in damaged m…
| Peptide | Mechanism | Half-Life | Typical Research Dose | IGF-1 Elevation (%) | Synergy Potential | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH receptor agonist | 6–8 days | 30–60 mcg/kg weekly | 60–80% |…
Melanotan II MC1R agonist, triggers eumelanin via cAMP-MITF pathway 0.5–1.0mg SC daily (loading), 0.5mg weekly (maintenance) 5–7 days visible, peak at 4–6 weeks SPF 3–4 per skin type increase Most researched, highest receptor aff…
Before selecting a peptide for memory research, understanding the comparative profiles across mechanism, dosing, timeline, and application context is essential. The table below distills clinical and preclinical evidence for the m…
This table compares the three peptides with the most compelling preclinical evidence for accelerating ulcer repair. BPC-157 VEGF receptor activation → angiogenesis + fibroblast proliferation Oral or subcutaneous 88% ulcer reducti…
BPC-157 Upregulates VEGF and FGF to increase capillary density; modulates TGF-β1 to reduce inflammatory cytokines Daily (250–500 mcg) Localized. Within 2–3 cm of plantar fascia Accelerates collagen synthesis and tensile strength …
Before implementing any peptide protocol, understanding mechanism differences determines which compounds address specific injury profiles. The table below compares primary mechanisms, documented applications, typical research dos…